硼替佐米治疗继发性浆细胞白血病1例并文献复习  

Secondary plasma cell leukemia treated with bortezomib-based regimens:one case report and literature review

作　　者：李增军 邹德慧 刘庆珍 邱录贵 

机构地区：[1]中国医学科学院血液学研究所血液病医院实验血液学国家重点实验室,天津300020

出　　处：《临床血液学杂志》2011年第5期514-516,共3页Journal of Clinical Hematology

基　　金：国家科技支撑计划项目(No:2008BAI61B01);天津市科技支撑计划项目(No:09ZCGYSF01000)

摘　　要：目的:探讨硼替佐米治疗浆细胞白血病的疗效。方法:报道1例继发性浆细胞白血病患者应用硼替佐米治疗的疗效,对硼替佐米治疗浆细胞白血病的相关文献进行复习。结果:该例患者经包括自体造血干细胞移植在内的多种治疗,二次复发并进展为继发性浆细胞白血病,经硼替佐米为基础的方案治疗后获得满意的近期疗效,文献复习显示硼替佐米治疗浆细胞白血病有效率高,耐受性好,但长期疗效尚难改善。结论:硼替佐米为基础的方案治疗浆细胞白血病可获得较好的近期疗效,可作为该类患者的一线治疗药物,但长期疗效尚需探讨新的治疗措施。Objective：To explore the effecti of bortezomib-based regimenon on plasma cell leukemia.Method：Repart one case of secondary plasma cell leukemia were treated with bortezomib-based regimen.The literature was reviewed on the bortezomib-based therapy for PCL.Result：The patient who was initially diagnosed as multiple myeloma,and was treated many times including auto-stem cell transplantation.After relapsed two times,the patient was progressed to secondary plasma cell leukemia.The patient was achieved satisfactory response was after treated with bortezomib-based regimen.The literature review found that there was a high remission rate and good tolerance by bortezomib-based regimen for PCL.Conclusion：Bortezomib-based regimencan achieve a satisfactory remission rate and could be first-line therapy for PCL,though long term remission required.

关 键 词：白血病 浆细胞性 继发性 硼替佐米 

分 类 号：R733.7[医药卫生—肿瘤]